Clinical Trials
27
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
3
11.1%
Completed
16
59.3%
Not yet recruiting
1
3.7%
Recruiting
5
18.5%
Terminated
1
3.7%
Withdrawn
1
3.7%
No approval data available
- A major Nature Medicine study of 28,841 individuals demonstrates that Perspectum's iron corrected T1 (cT1) MRI biomarker effectively predicts both liver-related and cardiac outcomes, establishing it as a valuable non-invasive alternative to liver biopsy. - Elevated cT1 levels (>800ms) were associated with a 30% increased risk of heart-related hospitalization, while higher levels (>875ms) led to a nine-fold increase in serious liver-related outcomes within four years. - The research provides compelling evidence for using multiparametric MRI to identify at-risk patients with metabolic dysfunction-associated steatotic liver disease (MASLD), potentially transforming clinical practice by enabling earlier intervention.
• New research validates quantitative MRI imaging as a reliable alternative to liver biopsies for assessing disease and monitoring treatment response in MASH patients. • A reduction of 80ms in cT1, measured by Perspectum's LiverMultiScan, predicts histological response to MASH therapies, offering a non-invasive biomarker for clinical trials. • The studies highlight the potential of non-invasive tests (NITs) to track liver health changes, potentially reducing reliance on invasive liver biopsies in MASH drug development. • Perspectum's LiverMultiScan, an FDA-cleared technology, offers a comprehensive assessment of liver health by quantifying disease activity, severity, fat, and iron content.
